BiPER Therapeutics has now secured €800k in bridge funding to help develop its novel BiP inhibitor, BPR001-615, for the treatment of gastrointestinal malignancies. The funding raised will assist in refining BPR001-615’s pathology and regulatory preclinical study and advance toward first-in-human trials.
BPR001-615, BiPER’s first clinical candidate, is currently only 6 months away from starting clinical trials. It has been demonstrated that the company’s animal model in gastrointestinal cancers could help bring treatment to patients with these types of ailments.
BiPER Therapeutics Strong Funding Support
BiPER Therapeutics has secured more than €2.5 million for the development of several drug candidates that selectively target cancer cells. The most recent €800,000 in bridge funding was from WiSEED and Quest for Health. Moreover, it also allows investors to take a more active stake in the healthcare technology.
CEO to Attend JP Morgan Healthcare Conference
Mehdi Chelbi will be present at the 2025 JP Morgan Healthcare Conference in San Francisco from January 13–16. This event will also be a perfect chance to present the results of the BiPER work and possible investors for expanding and further combating cancer.
Thanks to Investors and the Community
BiPER Therapeutics extends its gratitude to all Wiseeders-investors who joined the company’s mission. The company is expanding its efforts in the battle against cancer and continuing its progress in the creation of new remedies.
